StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT - Free Report) from a sell rating to a hold rating in a research note issued to investors on Wednesday.
Separately, HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of Galectin Therapeutics in a research note on Friday, November 15th.
Check Out Our Latest Report on Galectin Therapeutics
Galectin Therapeutics Price Performance
GALT traded up $0.06 during trading hours on Wednesday, hitting $2.82. 132,467 shares of the stock were exchanged, compared to its average volume of 145,807. Galectin Therapeutics has a 12 month low of $1.55 and a 12 month high of $4.27. The stock has a 50-day simple moving average of $2.69 and a 200-day simple moving average of $2.60. The stock has a market cap of $176.98 million, a price-to-earnings ratio of -3.77 and a beta of 0.62.
Institutional Trading of Galectin Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Traynor Capital Management Inc. lifted its stake in Galectin Therapeutics by 23.5% during the second quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company's stock valued at $97,000 after purchasing an additional 8,164 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Galectin Therapeutics in the second quarter worth approximately $43,000. Rhumbline Advisers acquired a new position in Galectin Therapeutics in the 2nd quarter worth approximately $44,000. Geode Capital Management LLC raised its position in Galectin Therapeutics by 2.5% during the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company's stock valued at $2,372,000 after buying an additional 20,817 shares during the period. Finally, State Street Corp grew its stake in Galectin Therapeutics by 9.3% during the 3rd quarter. State Street Corp now owns 251,014 shares of the company's stock valued at $690,000 after acquiring an additional 21,399 shares in the last quarter. 11.68% of the stock is currently owned by institutional investors.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Read More
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
